<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100795">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845259</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-1 antipsychotics</org_study_id>
    <secondary_id>2013-000121-31</secondary_id>
    <secondary_id>U1111-1128-3404</secondary_id>
    <nct_id>NCT01845259</nct_id>
  </id_info>
  <brief_title>Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?</brief_title>
  <acronym>GREAT</acronym>
  <official_title>Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psychiatric Centre Rigshospitalet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Psychiatric Centre Rigshospitalet</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major
      clinical problems among antipsychotic-treated patients. Especially two of the most
      efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic
      disturbances and can rarely be replaced by other drugs due to the effectiveness of the
      compounds. Glucagon-like peptide 1 (GLP-1) has improved glycemic control among patients with
      type 2 diabetes. The study will investigate whether the beneficial effects of GLP-1
      analogues on glycemic control in type 2 diabetic patients, can be extended to a population
      of non-diabetic, dysglycemic psychiatric patients, receiving antipsychotic medical
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>Baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Glucose tolerance (measured by area under the curve (AUC) for plasma glucose (PG) excursion following a 4-hour 75 g Oral Glucose Tolerance Test (OGTT))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysglycaemia</measure>
    <time_frame>Baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in dysglycaemia (Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), combined IFG/IGT or diabetes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Every 4 weeks from baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secretion of incretin hormons, insulin sensitivity and beta cell function</measure>
    <time_frame>Baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated by Homeostatic Model of Assessment (HOMA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dual energy x-ray absorptiometry (DEXA)-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile and liver function</measure>
    <time_frame>Every 4 weeks from baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychopathology</measure>
    <time_frame>Baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Schizophrenia Quality of Life Scale (SQLS), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement (CGI-I), Global Assessment of Function (GAF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Every 4 weeks from baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Every 4 weeks from baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Alcohol use</measure>
    <time_frame>Every 4 weeks from baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUDIT (Alcohol Use Disorder Identification Test)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes i dietary and exercise records</measure>
    <time_frame>Every 4 weeks from baseline - 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Impaired Glucose Tolerance Associated With Drugs</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once a day 1,8 mg subcutaneous injection for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once a day 1,8 mg subcutaneous injection for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Once a day 1,8 mg subcutaneous injection for 16 weeks</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
    <other_name>GLP-1 agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide Placebo</intervention_name>
    <description>Once a day 1,8 mg subcutaneous injection for 16 weeks</description>
    <arm_group_label>Liraglutide placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed oral and written consent

          -  Diagnosed with schizophrenia, schizotypal disorder or paranoid psychosis according to
             the criteria of ICD10 (International Classification of Diseases, World Health
             Organization) or the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, the American Psychiatric Association)

          -  and on stable antipsychotic treatment with either clozapine or olanzapine for at
             least 6 months (without dose change for at least 30 days)

          -  Stable co-medications for at least 30 days.

          -  Age ≥18 years and ≤65 years

          -  Stable weight (defined as less than 5% change in weight over the last 3 month before
             inclusion)

          -  BMI ≥27 kg/m2

          -  Dysglycaemia (IFG, i.e. fasting plasma glucose level from 6.1 mmol/L to 6.9 mmol/L or
             IGT, i.e. two-hour glucose levels of 7.8 to 11.0 mmol on the 75-g oral glucose
             tolerance test and a fasting plasma glucose of less than 7.0 mmol/L).

        Exclusion Criteria:

          -  Compulsory treatment

          -  Females of child bearing potential who are pregnant, breast-feeding or have intention
             of becoming pregnant or are not using adequate contraceptive measures

          -  Subjects treated with corticosteroids or other hormone therapy (except estrogens)

          -  Any active substance abuse or dependence for the past 6 months (except for nicotine)

          -  Impaired hepatic function (liver transaminases &gt;2 times upper normal limit)

          -  Impaired renal function (se-creatinine &gt;150 μM and/or macroalbuminuria)

          -  Impaired pancreatic function (acute or chronic pancreatitis and/or amylase &gt;2 times
             upper normal limit)

          -  Cardiac problems defined as decompensated heart failure (NYHA class III or IV),
             unstable angina pectoris and/or myocardial infarction within the last 12 months

          -  Uncontrolled hypertension (systolic blood pressure &gt;180 mmHg, diastolic blood
             pressure &gt;100 mmHg)

          -  Any condition that the investigator feels would interfere with trial participation

          -  Receiving any investigational drug within the last 3 months

          -  Use of weight-lowering pharmacotherapy within the preceding 3 month

          -  Type 1 or 2 diabetes with HbA1c &gt; 6.5%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Fink-Jensen, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric Centre Rigshospitalet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Vilsbøll, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Division, Gentofte</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anders Fink-Jensen, MD, DMSci</last_name>
    <phone>+45 22755843</phone>
    <email>a.fink-jensen@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie F Rask Larsen, MD</last_name>
    <phone>+45 22977757</phone>
    <email>dr.rask@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psychiatric Centre Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>København Ø</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Fink-Jensen, MD, DMsci</last_name>
      <phone>+45 22755843</phone>
      <email>a.fink-jensen@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Julie F Rask Larsen, MD</last_name>
      <phone>+45 22977757</phone>
      <email>dr.rask@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anders Fink-Jensen, MD, DMSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie F Rask Larsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://psyktreat.sharepoint.com</url>
    <description>Web page about the study for patients and caregivers</description>
  </link>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 5, 2013</lastchanged_date>
  <firstreceived_date>April 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric Centre Rigshospitalet</investigator_affiliation>
    <investigator_full_name>Anders Fink-Jensen, MD, DMSci</investigator_full_name>
    <investigator_title>Professor, MD, DMSci</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
